Meanwhile, a Phase II, single-arm, open-label study in China involved 84 patients with MET exon 14 skipping mutations who had positive pulmonary sarcomatoid carcinoma or other NSCLC subtypes and received savolitinib [30]. The gene discussed is MET; the disease is non-small cell lung carcinoma.